标题
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 10, Issue 12, Pages 688-696
出版商
Springer Nature
发表日期
2013-10-15
DOI
10.1038/nrclinonc.2013.177
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prostate Cancer and Prostatic Intraepithelial Neoplasia: True, True, and Unrelated?
- (2013) Ian M. Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer
- (2013) Melinda L. Telli JOURNAL OF CLINICAL ONCOLOGY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- How valid are claims for synergy in published clinical studies?
- (2012) A. Ocana et al. ANNALS OF ONCOLOGY
- Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
- (2012) Hsiao-Ching Chuang et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract 401: Inducible nitric oxide synthase suppresses the expression of CXCL10 and hence leads to the poor outcome of Stage III malignant melanoma
- (2012) Keiji Tanese et al. CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: A Gynecologic Oncology Group Study
- (2012) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes
- (2012) Steven E. Lipshultz et al. JOURNAL OF CLINICAL ONCOLOGY
- Why Do Phase III Clinical Trials in Oncology Fail so Often?
- (2012) L. Amiri-Kordestani et al. JNCI-Journal of the National Cancer Institute
- Abstract A226: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line.
- (2012) S. Licht et al. MOLECULAR CANCER THERAPEUTICS
- Abstract ED02-02: Phasing out phase III trials: How much evidence do we need if the target is clearly hit?
- (2012) J. Verweij MOLECULAR CANCER THERAPEUTICS
- Raise standards for preclinical cancer research
- (2012) C. Glenn Begley et al. NATURE
- Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
- (2011) Anne-Renee Hartman et al. CANCER
- Abstract P5-06-09: Cell Cycle Effects of Iniparib, a PARP Inhibitor, in Combination with Gemcitabine and Carboplatin in the MDA-MB-468(-) Triple-Negative Breast Cancer (TNBC) Cell Line
- (2011) V Ossovskaya et al. CANCER RESEARCH
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- 9006 ORAL Results of a Phase 2 Study of Gemcitabine/Cisplatin/lniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC
- (2011) S. Novello et al. EUROPEAN JOURNAL OF CANCER
- Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer
- (2011) Veronica Dussel et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
- (2011) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Delivering affordable cancer care in high-income countries
- (2011) Richard Sullivan et al. LANCET ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
- (2011) J. M. Senra et al. MOLECULAR CANCER THERAPEUTICS
- High drug attrition rates—where are we going wrong?
- (2011) Lisa Hutchinson et al. Nature Reviews Clinical Oncology
- Phase II failures: 2008–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Believe it or not: how much can we rely on published data on potential drug targets?
- (2011) Florian Prinz et al. NATURE REVIEWS DRUG DISCOVERY
- Phase III and submission failures: 2007–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- Translating Clinical Trials into Meaningful Outcomes
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Translating cancer research into targeted therapeutics
- (2010) J. S. de Bono et al. NATURE
- Preclinical development of molecular-targeted agents for cancer
- (2010) Alberto Ocana et al. Nature Reviews Clinical Oncology
- Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
- (2009) S Postel-Vinay et al. BRITISH JOURNAL OF CANCER
- Rapidly rising clinical trial costs worry researchers
- (2009) R. Collier CANADIAN MEDICAL ASSOCIATION JOURNAL
- In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016
- (2009) A. L. Russo et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
- (2009) Shahneen K. Sandhu et al. EUROPEAN JOURNAL OF CANCER
- Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide
- (2009) Kun Molecular Medicine Reports
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer
- (2008) Denise A. Yardley et al. Clinical Breast Cancer
- Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer
- (2008) David Loesch et al. Clinical Breast Cancer
- How basal are triple-negative breast cancers?
- (2008) François Bertucci et al. INTERNATIONAL JOURNAL OF CANCER
- Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through theBRCA2Promoter
- (2008) Jinhua Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway
- (2008) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Basal-Like Breast Cancer: A Critical Review
- (2008) Emad A. Rakha et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now